
Amphastar Pharmaceuticals AMPH
$ 28.8
4.54%
Quarterly report 2025-Q3
added 11-06-2025
Amphastar Pharmaceuticals Interest Expense 2011-2026 | AMPH
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Amphastar Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.08 M | -3.93 M | 9.07 M | 885 K | 374 K | 119 K | 243 K | 826 K | 1.02 M | 987 K | 609 K | 958 K | 784 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.07 M | -3.93 M | 1.23 M |
Quarterly Interest Expense Amphastar Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 231 K | 1.51 M | -2.23 M | - | -5.09 M | 298 K | 5.92 M | - | 3.46 M | -1.52 M | 398 K | - | 566 K | 397 K | 355 K | - | 527 K | 86 K | 104 K | - | 175 K | 35 K | 76 K | - | 22 K | 24 K | 30 K | - | 124 K | 100 K | 18 K | - | 264 K | 237 K | 191 K | - | 281 K | 305 K | 384 K | - | 232 K | 210 K | 341 K | - | 504 K | 476 K | 180 K | - | 195 K | 237 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.92 M | -5.09 M | 254 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Amarin Corporation plc
AMRN
|
8 K | $ 14.88 | 0.1 % | $ 6.07 B | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
4.68 M | $ 3.96 | 0.89 % | $ 338 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
Adagene
ADAG
|
1.11 M | $ 3.16 | 10.7 % | $ 178 M | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
AlloVir
ALVR
|
1.19 M | - | 4.14 % | $ 49.1 M | ||
|
Biogen
BIIB
|
268 M | $ 196.13 | 0.32 % | $ 28.7 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K | ||
|
Bristol-Myers Squibb Company
BMY
|
-674 M | $ 60.79 | 1.55 % | $ 124 B | ||
|
Alterity Therapeutics Limited
ATHE
|
2.28 K | $ 3.49 | -0.55 % | $ 8.4 B | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Athira Pharma
ATHA
|
3.96 M | - | - | $ 269 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-20.7 M | - | - | $ 1.01 B | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M | ||
|
Ascendis Pharma A/S
ASND
|
65.5 M | $ 215.79 | -1.06 % | $ 5 B | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | ||
|
Arena Pharmaceuticals
ARNA
|
4.16 M | - | -6.81 % | $ 3.04 B | ||
|
Brickell Biotech
BBI
|
5 K | - | -5.38 % | $ 6.06 M | ||
|
AgeX Therapeutics
AGE
|
4.9 M | - | -10.17 % | $ 12.2 K | ||
|
Athersys
ATHX
|
103 K | - | 3.77 % | $ 22.4 M | ||
|
CRISPR Therapeutics AG
CRSP
|
86.6 M | $ 52.89 | 8.09 % | $ 4.76 B | ||
|
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | ||
|
BeiGene, Ltd.
BGNE
|
-12.6 M | - | 0.49 % | $ 251 B | ||
|
Autolus Therapeutics plc
AUTL
|
9.29 M | $ 1.42 | 2.54 % | $ 362 M | ||
|
Amneal Pharmaceuticals
AMRX
|
11.8 M | $ 14.82 | 1.26 % | $ 4.58 B | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M |